Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Next Previous
X
Search
Trial Profile

A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimasertib (Primary)
  • Indications Adenocarcinoma; Colon cancer; Gallbladder cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Merck KGaA

    • Most Recent Events

    • 19 Oct 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 19 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
    • 05 Nov 2014 Planned number of patients changed from 48 to 80 according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top